Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
Miguel García-GrimshawJavier Andrés Galnares-OlaldeOmar Yaxmehen Bello-ChavollaAnaclara Michel-ChávezArturo Cadena-FernándezMaría Eugenia Briseño-GodínezNeftalí Eduardo Antonio-VillaIsaac NúñezAlonso Gutiérrez-RomeroLaura E Hernández-VanegasMaría Del Mar Saniger-AlbaRoger Carrillo-MezoSanta Elizabeth Ceballos-LiceagaGuillermo Carbajal-SandovalFernando Daniel Flores-SilvaJosé Luis Díaz-OrtegaRicardo Cortes-AlcaláJosé Rogelio Pérez-PadillaHugo Lopez-GatellErwin ChiqueteGustavo Reyes-TeránAntonio ArauzSergio Iván Valdés-FerrerPublished in: European journal of neurology (2022)
Guillain-Barré syndrome was an extremely infrequent AEFI against SARS-CoV-2. The protection provided by these vaccines outweighs the risk of developing GBS.